BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed RARE catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:ea46d07dad0a7a2f389e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:RARE P3 readout (est.): Setrusumab in Pediatric Japanese Subjects W
 ith Osteogenesis Imperfecta
DESCRIPTION:Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imp
 erfecta\nNCT06636071 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Ultrageny
 x Pharmaceutical Inc\nPrimary completion date (ESTIMATED)\; top-line resul
 ts usually follow later.\nDate precision: month (shown on the first day)\n
 Ticker RARE (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT
 06636071\nScheduling/reference data from public records\; dates can move. 
 Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06636071
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:58e5b4fc59974788153f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260919
DTEND;VALUE=DATE:20260920
SUMMARY:RARE PDUFA (company-disclosed): apazunersen
DESCRIPTION:PDUFA September 19\, 2026 - Ultragenyx Pharmaceutical Inc. (apa
 zunersen)\nConfidence: company-disclosed\nTicker RARE (confidence 1.0)\nSo
 urce: https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/r
 are-ex99_1.htm\nScheduling/reference data from public records\; dates can 
 move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:d1710f32f22254e4b237@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260823
DTEND;VALUE=DATE:20260824
SUMMARY:RARE PDUFA (company-disclosed): rebisufligene
DESCRIPTION:PDUFA August 23\, 2026 - Ultragenyx Pharmaceutical Inc. (rebisu
 fligene)\nConfidence: company-disclosed\nTicker RARE (confidence 1.0)\nSou
 rce: https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/ra
 re-ex99_1.htm\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
BEGIN:VEVENT
UID:ddbc00417a75f90ee173@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260701
DTEND;VALUE=DATE:20260702
SUMMARY:RARE PDUFA (company-disclosed): PDUFA second half of 2026 - Ultrage
 nyx Pharmaceutical Inc.
DESCRIPTION:PDUFA second half of 2026 - Ultragenyx Pharmaceutical Inc.\nCon
 fidence: company-disclosed\nDate precision: half (shown on the first day)\
 nTicker RARE (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/
 data/1515673/000119312526332802/rare-ex99_1.htm\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare
 -ex99_1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
END:VCALENDAR
